eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Review paper

Rhabdomyosarcoma in children – current pathologic and molecular classification

Ireneusz Dziuba, Paweł Kurzawa, Michał Dopierała, Ana B. Larque, Danuta Januszkiewicz-Lewandowska

Pol J Pathol 2018; 69 (1): 20-32
Online publish date: 2018/05/07
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The last 25 years have brought significant progress in the treatment of sarcomas in children, especially rhabdomyosarcoma (RMS). Nevertheless, treatment failure in some patients results from considerable biological heterogeneity noted in these tumours. RMS, the most common malignant soft tissue neoplasm in children, includes two main subtypes: embryonal (ERMS) and alveolar (ARMS). Due to greater aggressiveness and worse prognosis of ARMS in comparison to ERMS, discrimination between different rhabdomyosarcoma subtypes is of crucial clinical importance. This paper presents the current histological classification of RMS, up-to-date immunohistochemical and biological research regarding RMS, and its associated clinical and prognostic significance.

rhabdomyosarcoma, children, pathologic and molecular classification

Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 2002; 4: 21-28.
Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59: 5-10.
Tarnowski M, Grymuła K, Tkacz M, et al. Molekularne mechanizmy regulacji przerzutowania komórek nowotworowych na przykładzie mięsaka prążkowanokomórkowego (rhabdomyosarcoma). Postepy Hig Med Dosw 2014; 68: 258-257.
Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006; 5: 816-822.
Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997; 19: 483-491.
Gurney JG, Severson RK, Davis, et al. Incidence of cancer in children in United States. Sex-race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75: 2186-2195.
Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999; 4: 34-44.
Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011; 12: 559-567.
Knapke S, Zelley K, Nichols KE, et al. Identification, management, and evaluation of children with cancer-predisposition syndromes. Am Soc Clin Oncol Educ Book 2012; 2012: 576-584.
Bennicelli JL, Advani S, Schäfer BW, et al. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999; 18: 4348-4356.
Scrable H, Witte D, Shimada H, et al. Molecular differentia pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1989; 1: 23-25.
Slominski A, Wortsman J, Carlson A, et al. Molecular pathology of soft tissue and bone tumors. A review. Arch Pathol Lab Med 1999; 123: 1246-1259.
Merlino G, Helman LJ. Rhabdomyosarcoma – working out the pathways. Oncogene 1999; 18: 5340-5348.
Fletcher CD, Bridge JA, Hogendoorm PC, et al. WHO Classification of tumours of soft tissue and bone. World Health Organization Classification of Tumours. IARC Press, Lyon 2013; 125-135.
Rudzinski E. Histology and fusion status in rhabdomyosarcoma. Am Soc Clin Oncol Educ Book 2013; 2013: 425-428.
Kodet R, Fajstavr J, Kabelka Z, et al. Is fetal cellular rhabomyoma an entity or a differentiated rhabdomyosarcoma? A study of patients with rhabdomyoma of the tongue and sarcoma of the tongue enrolled in the intergroup rhabdomyosarcoma studies I, II and III. Cancer 1991; 67: 2907-2913.
Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006; 130: 1454-1465.
Rudzinski ER, Anderson JR, Hawkins DS, et al. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children’s Oncology Group. Arch Pathol Lab Med 2015; 139: 1281-1287.
Rekhi B, Upadhyay P, Ramteke MP, et al. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes. Mod Pathol 2016; 29: 1532-1540.
Carroll SJ, Nodit L. Spindle cell rhabdomyosarcoma: a brief diagnostic review and differential diagnosis. Arch Pathol Lab Med 2013; 137: 1155-1158.
Matthew R. Lindberg. Soft Tissue Immunohistochemistry. Tumors of Sceletal Muscle Malignant. In: Diagnostic Pathology: Soft Tissue Tumors. 2nd Edition. Tumors of skeletal muscles, malignant. Elsevier 2017; 10-15, 372-397.
Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 2000; 156: 399-408.
Hostein I, Andraud-Fregeville M, Guillou L, et al. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 2004; 101: 2817-2824.
Morotti RA, Nicol KK, Parham DM et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children’s Oncology Group experience. Am J Surg Pathol 2006; 30: 962-968.
Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006; 24: 816-822.
Leuschner I, Langhans I, Schmitz R, et al. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumour Registry and the German Cooperative Soft Tissue Sarcoma Study. Pediatr Dev Pathol 2003; 6: 128-136.
Jain S, Xu R, Prieto VG, et al. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 2010; 3: 416-428.
Bishop JA, Thompson LD, Cardesa A, et al. Rhabdomyoblastic differentiation in head and neck malignancies other than rhabdomyosarcoma. Head Neck Pathol 2015; 9: 507-518.
Alexandrescu S, Akhavanfard S, Harris MH, et al. Clinical, pathologic, and genetic features of Wilms tumors with WTX gene mutation. Pediatr Dev Pathol 2017; 20: 105-111.
Homma T, Hemmi A, Ohta T et al. A rare case of a pineoblastoma with a rhabdomyoblastic component. Neuropathology 2017; 37: 227-232.
Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 2002; 20: 2672-2679.
El Demellawy D, McGowan-Jordan J, de Nanassy J, et al. Update on molecular findings in rhabdomyosarcoma. Pathology 2016; 49: 238-246.
Hawkins DS, Gupta AA, Rudzinski ER. What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr 2014; 26: 50-56.
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013; 20: 387-397.
Hornick JL. Biologic Potential, Grading, Staging, and Reporting of Sarcomas in: Practical Soft Tissue Pathology: Diagnostic Approach; Biological Potential, Grading, Staging and Reporting of Sarcomas, Hornick JL. (ed.), Elsevier, Philadelphia 2013; 7-10.
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-99.
Coindre JM. Grading of soft tissue sarcomas, review and update. Arch Pathol Lab Med 2006; 130: 1448-1453.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe